A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Aspord, Caroline ^a,b,c   Charles, Julie ^a,b,c,d   Leccia, Marie Therese ^b,c,d   Laurin, David ^a,b,c   Richard, Marie Jeanne ^b,c,d   Chaperot, Laurence ^a,b,c   Plumas, Joel ^a,b,c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIV GRENOBLE ALPES   (France)

^c INSERM   (France)

^d HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; HLA A ANTIGEN; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STAGING; CELL ISOLATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; SOLID TUMOR;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE PROGRESSION; EPITOPES; HEALTH; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; MELANOMA; MICE; NEOPLASM STAGING; PEPTIDES; T-LYMPHOCYTES; TISSUE DONORS; VACCINATION;

EID: 77956283741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010458     Document Type: Article

References (55)

1. Finn OJ (2008) Cancer immunology. N Engl J Med 358: 2704-2715. Review.
2. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, et al. (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678.
3. Palucka AK, Dhodapkar MV, Paczesny S, Ueno H, Fay J, et al. (2005) Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother 28: 158-168.
4. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393. Review.
5. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
6. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306. Review.
7. Fajardo-Moser M, Berzel S, Moll H (2008) Mechanisms of dendritic cell-based vaccination against infection. Int J Med Microbiol 298: 11-20. Review.
8. Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
9. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226.
10. Liu YJ (2005) IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors. Annu Rev Immunol 23: 275-306.
11. Kim R, Emi M, Tanabe K, Arihiro K (2007) Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121(2): 149-57.
12. Marañón C, Desoutter JF, Hoeffel G, Cohen W, Hanau D, et al. (2004) Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A 101: 6092-6097.
13. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837.
14. Villadangos JA, Young L (2008) Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 29: 352-361.
15. Lui G, Manches O, Angel J, Molens JP, Chaperot L, et al. (2009) Plasmacytoid dendritic cells capture and cross-present viral antigens from influenz-virus infected cells. Plos One - In press.
16. Cella M, Facchetti F, Lanzavecchia A, Colonna M (2000) Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 1: 305-310.
17. Fonteneau JF, Gilliet M, Larsson M, Dasilva I, Münz C, et al. (2003) Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 101: 3520-3526.
18. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, et al. (2003) Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 33: 1052-1062.
19. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, et al. (2004) CpG-A and CpG-B oligonucleotides differentially enhance human peptidespecific primary and memory CD8+ T-cell responses in vitro. Blood 103: 2162-2169.
20. Sapoznikov A, Fischer JA, Zaft T, Krauthgamer R, Dzionek A, et al. (2007) Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J Exp Med 204: 1923-1933.
21. Schlecht G, Garcia S, Escriou N, Freitas AA, Leclerc C, et al. (2004) Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 104: 1808-1815.
22. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, et al. (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200: 255-268.
23. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, et al. (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63: 6478-6487.
24. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, et al. (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7: 1339-1346.
25. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, et al. (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10: 7466-7474.
26. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, et al. (2007) Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763-2769.
27. Palamara F, Meindl S, Holcmann M, Lührs P, Stingl G, et al. (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173: 3051-3061.
28. Furumoto K, Soares L, Engleman E, Merad M (2004) Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113: 774-783.
29. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, et al. (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13: 2961-2969.
30. Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, et al. (2008) Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14: 4532-4542.
31. Liu C, Lou Y, Lizée G, Qin H, Liu S, et al. (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118: 1165-1175.
32. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest. 117(5): 1184-94. Review.
33. Mitchison NA, O'Malley C (1987) Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur J Immunol 17: 1579-1583.
34. Medzhitov R, Janeway CA, Jr. (1998) Innate immune recognition and control of adaptive immune responses. Semin Immunol 10: 351-353. Review.
35. Gjertsen HA, Lundin KE, Hansen T, Thorsby E (1993) T cells specific for viral antigens presented by HLA-Dw4 recognize DR13 on allogeneic cells: a possible mechanism for induction of rejection. Transpl Immunol 1: 126-131.
36. Muir G, Rajbabu K, Callen C, Fabre JW (2006) Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer. BJU Int 98: 989-995.
37. Fabre JW (2001) The allogeneic response and tumor immunity. Nat Med 7: 649-652. Review.
38. Blom B, Ho S, Antonenko S, Liu YJ (2000) Generation of interferon alphaproducing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 192: 1785-1796.
39. Chaperot L, Blum A, Manches O, Lui G, Angel J, et al. (2006) Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176: 248-255.
40. Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens JP, Chaperot L, et al. (2009) TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood 114(9): 1794-802.
41. Lui G, Manches O, Angel J, Molens JP, Chaperot L, et al. (2009) Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One 4(9): e7111.
42. Aspord C, Yu CI, Banchereau J, Palucka AK (2007) Humanized Mice for Development and Testing of Human Vaccines. Expert Opin Drug Discov 2: 949-960. Review.
43. Schettini J, Mukherjee P (2008) Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Clin Dev Immunol;DOI: 10.1155/ 2008/106321.
44. Newton DA, Romano C, Gattoni-Celli S (2000) Semiallogeneic cell hybrids as therapeutic vaccines for cancer. J Immunother 23: 246-254.
45. Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, et al. (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54: 663-670.
46. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, et al. (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19: 1621-1627.
47. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, et al. (2007) Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 56(12): 2003-16.
48. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, et al. (2004) Vaccination with hybrids of tumor and dendritic cells induces tumor-specific Tcell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110(5): 730-40.
49. Abe M, Wang Z, de Creus A, Thomson AW (2005) Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transplant 5(8): 1808-19.
50. Di Pucchio T, Chatterjee B, Smed-Sörensen A, Clayton S, Palazzo A, et al. (2008) Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 9(5): 551-7.
51. Young LJ, Wilson NS, Schnorrer P, Proietto A, ten Broeke T, et al. (2008) Differential MHC class II synthesis and ubiquitination confers distinct antigenpresenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol 9(11): 1244-52.
52. van den Hoorn T, Neefjes J (2008) Activated pDCs: open to new antigenpresentation possibilities. Nat Immunol 9(11): 1208-10.
53. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626.
54. Masterson AJ, Sombroek CC, De Gruijl TD, Graus YM, van der Vliet HJ, et al. (2002) MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 100(2): 701-3.
55. Santegoets SJ, Schreurs MW, Masterson AJ, Liu YP, Goletz S, et al. (2006) In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother 55(12): 1480-90.